Breaking News just issued 6/19/19 9:00 AM Eastern
(NYSE: TMO) Thermo Fisher Scientific and (OTC: PRED) Predictive Laboratories Announce Global Infertility Research Collaboration
Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment
CARLSBAD, Calif., June 19, 2019 /PRNewswire/ — Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., (OTC PINK: PRED) focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher’s various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as “unexplained.” The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology (ACOG) reports that at least 40 percent of women with infertility have endometriosis.
Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
“Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions,” said Bradley Robinson, CEO of Predictive Technology Group. “Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution.”
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
“We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women,” said Yan Zhang, general manager, reproductive health at Thermo Fisher. “With the combination of our partner’s expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Biotech Company Growing Revenues, Seeking NASDAQ Listing
PRED is bringing the future of medicine to the present
Good day everyone,
We are continuing our coverage of Predictive Technology Group, Inc. (OTC: PRED), a company that aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics.
PRED shares have had a tremendous spring. Trading under $2.00 per share in March and jumping to over $6.00 recently. The past few trading sessions have seen the share price soften as traders take some well-deserved profits. This share price consolidation has created a potential opportunity for our members. The catalysts and financial metrics that drove the PRED shares higher are not only still in place, but getting better. Do your due diligence and pick an entry level.
PRED currently derives the majority of its revenues (exceeding $10 million per quarter) from the cellular therapy division that provides products derived from amniotic tissue and Wharton’s Jelly that are used by physicians in a variety of healing applications. The company is not required to conduct clinical trials for its cellular therapy products because they do not make efficacy claims.
To facilitate revenue growth, the company may focus efforts on obtaining FDA approval for its suite of diagnostic tests and allogenic cell products. They could also become a supplier of cellular products to strategic partners in areas such as oncology and orthobiologics as well as a provider of inventory to tissue banks.
Predictive also intends to bring drugs to the market. Last month the company signed letter of intent with IQVIA (Formerly Quintiles and IMS) to guide the regulatory FDA process for potential drugs beginning with CoreCyte™ for osteoarthritis of the knee.
Also last month, the company announced that Predictive Laboratories has reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain. It’s possible this study could lead to a reduction in the use of opioids.
The company’s substantial cash flow ($3.1 million last quarter) can help to facilitate the development of new products that require clinical trials.
PRED has a proprietary genealogy database with over 30 million individuals and greater than 300,000 DNA samples, a valuable resource that can isolate genes that are implicated in disease and generate tests that are highly accurate.
PRED has articulated a growth plan for each of its four segments. Predictive Biotech will continue with cellular therapy products, which do not make any efficacy claims while Predictive Therapeutics will pursue products that require review and approval from the FDA. CellSure will focus on procurement of tissue, optimizing cell yields and quality and offering storage services for new mothers. Predictive Laboratories, created through the acquisition of Taueret, will continue to develop and commercialize genetic diagnostic tests.
Predictive’s marketing efforts in cellular therapy consists of over 20 sales team members and over 75 distributors that will target the naturopathic physicians, chiropractors, orthopedists, anti-aging, and cosmetic medicine and other specialties. The sales team, formerly consultants at Predictive, have only been employees for a couple of months.
Predictive’s products include:
AmnioCyte is a minimally manipulated human tissue allograft derived from amniotic fluid.
AmnioCyte Plus is a minimally manipulated human tissue allograft derived from the extracellular matrix of the amniotic membrane.
PolyCyte is a minimally manipulated human tissue allograft derived from the Wharton’s jelly of the umbilical cord.
CoreCyte is a minimally manipulated human tissue allograft derived from the Wharton’s jelly of the umbilical cord.
ARTguide is the first, non-invasive, integrated test for endometriosis and genetic causes of infertility.
PG Plus helps healthcare providers prevent adverse drug reactions by providing genomic information.
We believe the anticipated uplist to the NASDAQ may send PRED shares soaring. Many institutions and funds are precluded from investments in OTC companies. A NASDAQ listing could open the floodgates for those types of investors.
There is increasing demand for the company’s human cell and tissue products.
Gross profit margin for first nine months of fiscal 2019 was 63.8%.
Cash provided by operating activities for or the nine months ended March 31, 2019 was $3.1 million.
PRED has a fiscal year end of June 30th, so their Q4 and year end data will be forthcoming in the near term. If that data confirms the continuation of good financial results and corporate developments, it could act as a significant catalyst for the company’s shares.
Senator Orrin Hatch lends a great deal of credibility to the company’s board. Hatch was one of 58 senators who signed a letter directed to President George W. Bush, requesting the relaxing of federal restrictions on embryonic stem cell research. In 2010, Hatch’s bill was reauthorized which allowed stem cells from umbilical cords to be used to find treatment options.
Predictive’s work with cellular therapy could have implications beyond the current scope of their operations. The technology is so new, we don’t yet know the possibilities, or the impact it could have on the treatment of many diseases.
In the year 2000, science completed the mapping of the human genome and many thought “this is really going to change medicine down the road”. Here we go.
Always bringing you the best under the radar stories in the small cap arena,
The Traders News Group
Predictive Technology (PRED) and Regenerative Medicine
TradersNewsSource.com collects your contact information to keep you informed about updates to our web site, newsletters and social channels. All information is kept secure, with only authorized employees having access.
TradersNewsSource.com does from time to time, issue releases to subscribers as “Feature Reports” that may be related to our content partners or advertising sponsors.
We do not sell your contact information to other organizations for commercial purposes. We will not release your email address to anyone, unless you specifically give us permission to do so. Should you decide in the future to unsubscribe from TradersNewsSource.com at any time, simply follow the instructions located at the bottom of each newsletter edition. Your email address will be kept strictly confidential, and will never be shared with anyone for any purpose of any kind.
Regarding Google ads:
ALL STOCKS INVOLVE RISKS AND THE POSSIBILITY OF LOSING ALL OF YOUR INVESTMENT. PLEASE CONSIDER ALL RISKS BEFORE INVESTING.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated fifteen thousand dollars cash via bank wire by Banner Enterprises LLC for this weeks coverage of PRED. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.